Envista Holdings Corp Stock Price, News & Analysis

Envista Holdings Corporation (NYSE: NVST) reported a 1.3% sales increase to $645.8 million for Q2 2022, with core sales growth of 4%. Net income reached $44.5 million ($0.25 per diluted share), while adjusted net income was $86 million ($0.48 per diluted share), up from $0.46 in Q2 2021. Adjusted EBITDA rose to $126.9 million. CEO Amir Aghdaei noted ongoing supply chain challenges and geopolitical uncertainties but highlighted success in acquisitions, namely Carestream Dental's IOS business and Osteogenics' solutions. However, the company adjusted its 2022 guidance, anticipating mid-single digit core sales growth.

Envista Holdings announced an extension of its partnership with dentalcorp, Canada's largest dental service organization. This collaboration aims to enhance implant treatment capabilities across over 500 dentalcorp practices. Nobel Biocare, a subsidiary of Envista, will provide comprehensive support and training to more than 1,500 dentists within dentalcorp's network. This partnership emphasizes Envista's commitment to supporting dental professionals and improving patient care, focusing on digital and personalized solutions in the dental sector.

Envista Holdings Corporation (NYSE: NVST) will announce its financial results for Q2 2022 on August 3, 2022. A conference call is scheduled for 2:00 PM PT that same day, accessible via phone or webcast. Investors can expect a detailed discussion of the results, which will be accompanied by a slide presentation available on Envista's website. This call aims to provide insights into the company's performance, reflecting its commitment to enhancing customer care through a comprehensive range of dental solutions.

Envista Holdings Corporation (NYSE: NVST) will participate in the Stifel 2022 Jaws & Paws Conference on June 1, 2022, from 9:45 to 10:15 AM EST in New York City. Investors can access live streams or recordings via the company's Investor Relations website. Envista is a leading global dental products company, comprising over 30 trusted brands that offer dental consumables, solutions, and technology. The company focuses on improving patient care and is well-positioned in attractive segments of the dental industry.

Envista Holdings Corporation (NYSE: NVST) announced on May 17, 2022, that it has entered into a definitive agreement to acquire Osteogenics Biomedical Inc, Allotech LLC, and OBI Biologics, collectively referred to as Osteogenics. The deal aims to enhance Envista's regenerative solutions for dental professionals and is expected to close in Q3, pending regulatory approvals. Osteogenics is recognized for innovative bone grafting products, primarily marketed under the Cytoplast brand. The acquisition aligns with Envista's strategy to innovate in oral care and strengthen its market position.

Envista Holdings Corporation (NYSE: NVST) will participate in the William Blair Emerging Technologies in Dental Care Virtual Conference on May 17, 2022, from 7:00 to 7:45 AM PT. Investors can access recordings via the company’s Investor Relations website. Envista, a leading global dental products company, operates over 30 trusted brands and offers a comprehensive portfolio of dental solutions and technologies aimed at improving patient care. Its commitment to innovation and customer focus positions it as a key player in the dental industry.

Envista Holdings Corporation (NYSE: NVST) reported a 3.1% increase in sales for Q1 2022, totaling $631.4 million, with a core sales growth of 5.4%. Net income was $70.4 million or $0.39 per diluted share. Adjusted net income was $84.9 million or $0.47 per diluted share, down from $0.49 a year prior. Adjusted EBITDA was $124.6 million, reflecting a margin of 19.7%. The company anticipates additional sales of $35 - $45 million from its newly acquired DEXIS IOS business and maintains a core sales growth forecast of 6% - 8% for 2022.

Envista Holdings Corporation (NYSE: NVST) has successfully acquired Carestream Dental's Intraoral Scanner business, which will be rebranded as DEXIS. This business is crucial for digital workflows in dental procedures such as implants and aligners, positioning Envista to enhance its offerings. CEO Amir Aghdaei emphasized the strategic importance of this acquisition in improving patient care through advanced dental technology. Notably, the transaction excludes Carestream Dental's Imaging Equipment and Practice Management businesses. Further transaction details will be provided in a forthcoming SEC filing.

Envista Holdings Corporation (NYSE: NVST) will release its first quarter 2022 financial results on May 4, 2022. A conference call to discuss these results is scheduled for 2:00 PM PT on the same day, lasting approximately one hour. The call will be accessible via phone or through a webcast on the company's website. Materials related to the earnings will be available on the Investors section of Envista's site prior to the call and afterward. Envista is a leading global dental products company with a focus on improving patient care through innovative solutions.